(Z)-6-(3-methyl-5-isoxazolyl)methylene-1-azabicyclo[3.2.1]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: (Z)-6-(3-methyl-5-isoxazolyl)methylene-1-azabicyclo[3.2.1]octane
• 英文别名: 6-(3-Methyl-isoxazol-5-ylmethylene)-1-aza-bicyclo[3.2.1]octane；5-[(Z)-1-azabicyclo[3.2.1]octan-6-ylidenemethyl]-3-methyl-1,2-oxazole
• 化学式: C₁₂H₁₆N₂O
• 分子量: 204.272
• InChiKey: ARZOYSBDVRQNMW-IZZDOVSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  29.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-氮杂双环[3.2.1]辛烷-6-酮 、 3-methyl-5-(trimethylsilylmethyl)isoxazole 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.0h， 生成 (E)-6-(3-methyl-5-isoxazolyl)methylene-1-azabicyclo[3.2.1]octane 、 (Z)-6-(3-methyl-5-isoxazolyl)methylene-1-azabicyclo[3.2.1]octane
  参考文献：
  名称：

  Identification of novel (isoxazole)methylene-1-azabicyclic compounds with high affinity for the central nicotinic cholinergic receptor

  摘要：

  A novel class of compounds with high affinity (IC50 = 3.4 - 500 nM) for the central nicotinic cholinergic receptor was synthesized, The compounds were characterized in vitro and in vivo and compared to ABT 418 and nicotine. The new ligands are effective nicotinic compounds with biological profiles distinguishable from reference compounds. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00347-8

文献信息

• THE USE OF HETEROCYCLIC COMPOUNDS
  申请人：NOVO NORDISK A/S

  公开号：EP0809494A1

  公开（公告）日：1997-12-03
• [EN] THE USE OF HETEROCYCLIC COMPOUNDS<br/>[FR] UTILISATION DE COMPOSES HETEROCYCLIQUES
  申请人：NOVO NORDISK A/S

  公开号：WO1996025160A1

  公开（公告）日：1996-08-22

  (EN) The present invention relates to the use of therapeutically active azabicyclic compounds of formula (I) wherein p is 1 and either m is 0 and n is 1 or 2 or m is 1 and n is 1, or p is 2, m is 0 and n is 1; and wherein Y is (a) and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the nicotinic cholinergic system.(FR) La présente invention concerne l'utilisation de composés azabicycliques, actifs sur le plan thérapeutique, ayant la formule (I) dans laquelle p vaut 1 et, soit m vaut 0 et n vaut 1 ou 2, soit m vaut 1 et n vaut 1, ou bien p vaut 2, m vaut 0 et n vaut 1, et dans laquelle Y signifie (a). L'invention concerne aussi des compositions pharmaceutiques comprenant ces composés. Ces composés nouveaux sont utiles pour traiter les affections du système nerveux central causées par un dysfonctionnement du système cholinergique nicotinique.
• Identification of novel (isoxazole)methylene-1-azabicyclic compounds with high affinity for the central nicotinic cholinergic receptor
  作者：P.H. Olesen、M.D.B. Swedberg、K. Eskesen、M.E. Judge、J. Egebjerg、J.E. Tønder、T. Rasmussen、M.J. Sheardown、K. Rimvall

  DOI：10.1016/s0960-894x(97)00347-8

  日期：1997.8

  A novel class of compounds with high affinity (IC50 = 3.4 - 500 nM) for the central nicotinic cholinergic receptor was synthesized, The compounds were characterized in vitro and in vivo and compared to ABT 418 and nicotine. The new ligands are effective nicotinic compounds with biological profiles distinguishable from reference compounds. (C) 1997 Elsevier Science Ltd.